Tradestie Institutional Equity Comparison Engine
FCN vs ASTH โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
FCN Overall Edge
FCN Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to FTI Consulting, Inc. (FCN) driven by superior Valuation, Growth & Margin, Options & Structure while ASTH counters with relative strength in Momentum & Technical. Fundamentally, FCN trades at 18.2x Forward P/E with 10.3% operating margin (+5.9% YoY revenue) versus ASTH at 9.1x Forward P/E and 2.6% operating margin (+7.1% YoY). In options structure, FCN sits in SURGE (8th %ile IV; Dealer Gamma Walls on Pro) against ASTH sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
FCN
FCN 18.2x vs ASTH 9.1x Fwd P/E
Growth & Margin Winner
FCN
Op Margin 10.3% vs 2.6% ยท YoY +5.9% vs +7.1%
Momentum & Technical Winner
ASTH
1Y +25.3% vs +50.3% ยท 52W Pos 98% vs 44%
Options & Structure Winner
FCN
SURGE (8th %ile IV) vs BREAKDOWN (11th %ile IV)
FCN
NYSE
FTI Consulting, Inc.
Services-Management Consulting Services
$206.76
+1.95% 1D
Market Cap
$5.4B
1M Return
+39.2%
1Y Return
+25.34%
Forward P/E
18.2x
Unified AI Score
30.4 / 100
SELL
Tech 50.0
Fund 34.0
Flow 68.0
Mom 40.0
ASTH
NASDAQ
Astrana Health Inc. Common Stock
Services-Management Consulting Services
$32.94
+3.58% 1D
Market Cap
$1.6B
1M Return
-10.51%
1Y Return
+50.34%
Forward P/E
9.1x
Unified AI Score
53.2 / 100
HOLD
Tech 59.0
Fund 56.0
Flow 59.0
Mom 56.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
FCN +25.34%
ASTH +50.34%
Spread: +25.0 pp (ASTH Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FCN Revenue | ASTH Revenue | FCN Op. Margin | ASTH Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $2.03B | $520M | 11.1% | 17.0% | ASTH |
| FY2019 | $2.35B | $560M | 13.0% | 5.8% | FCN |
| FY2020 | $2.46B | $690M | 11.5% | 11.7% | ASTH |
| FY2021 | $2.78B | $770M | 11.2% | 12.7% | ASTH |
| FY2022 | $3.03B | $1.14B | 10.0% | 9.1% | FCN |
| FY2023 | $3.49B | $1.39B | 10.8% | 6.1% | FCN |
| FY2024 | $3.70B | $2.03B | 9.4% | 4.4% | FCN |
| FY2025 | $3.79B | $3.18B | 10.3% | 2.5% | FCN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | FCN | ASTH | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $5.4B | $1.6B | Larger Scale | FCN |
| Trailing P/E Ratio Valuation | 24.7x | 30.6x | Lower Multiple | FCN |
| Forward P/E Ratio Valuation | 18.2x | 9.1x | Lower Multiple | ASTH |
| Revenue Growth (YoY) Growth | +5.9% | +7.1% | Higher Growth | ASTH |
| Operating Margin (TTM) Profitability | 10.3% | 2.6% | Higher Margin | FCN |
| Net Profit Margin Profitability | 5.9% | 1.4% | Higher Margin | FCN |
| Return on Equity (ROE) Capital Efficiency | 15.2% | 9.8% | Higher ROE | FCN |
| 52-Week Range Position Momentum | 98% ($129โ$209) | 44% ($18โ$52) | Stronger Trend | FCN |
| Beta / 30D Volatility Risk Regime | -0.49ฮฒ ยท 54% Vol | 0.40ฮฒ ยท 60% Vol | Lower Realized Risk | FCN |
| Unified Institutional Score Composite Signal | 30.4 / 100 (SELL) | 53.2 / 100 (HOLD) | Higher Composite | ASTH |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full FCN vs ASTH Buy Guide
FCN
SURGE
8d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
8th %ile
IV Regime
Compressed (<25th %ile)
ASTH
BREAKDOWN
96d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
11th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither FCN nor ASTH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.